NHS Offers Game-Changing Treatment for Blood Cancer Patients
Breakthrough Medication Now Available
The UK National Institute for Health and Care Excellence (NICE) has published recommendations for the use of BeiGene's Zanubrutinib (Brukinsa) on the National Health Service (NHS) in England. This decision expands access to a revolutionary treatment for hundreds of blood cancer patients.
Take-Home Tablet with Remarkable Benefits
Zanubrutinib is administered as a take-home tablet, offering a convenient and flexible treatment option for patients. It has shown promising results in treating various forms of blood cancer, including mantle cell lymphoma and chronic lymphocytic leukemia.
A Path Forward for Patients
The NICE recommendation is a significant step in providing access to innovative treatments that can improve the lives of blood cancer patients. Zanubrutinib offers the potential for better control of the disease, reduced side effects, and improved quality of life.
The cost of Zanubrutinib is £492,865 per 120-pack of 80-mg capsules (excluding VAT). Patients are advised to consult with their healthcare providers for further information and guidance on accessing this treatment.
Comments